HK1055730A1 - Benzazole derivatives and their use as jnk modulators - Google Patents

Benzazole derivatives and their use as jnk modulators

Info

Publication number
HK1055730A1
HK1055730A1 HK03107978A HK03107978A HK1055730A1 HK 1055730 A1 HK1055730 A1 HK 1055730A1 HK 03107978 A HK03107978 A HK 03107978A HK 03107978 A HK03107978 A HK 03107978A HK 1055730 A1 HK1055730 A1 HK 1055730A1
Authority
HK
Hong Kong
Prior art keywords
benzazole derivatives
jnk modulators
jnk
modulators
benzazole
Prior art date
Application number
HK03107978A
Other languages
English (en)
Inventor
Serge Halazy
Dennis Church
Montserrat Camps
Pascale Gaillard
Jean-Pierre Gotteland
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of HK1055730A1 publication Critical patent/HK1055730A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK03107978A 1999-12-24 2003-11-05 Benzazole derivatives and their use as jnk modulators HK1055730A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99811207A EP1110957A1 (en) 1999-12-24 1999-12-24 Benzazole derivatives and their use as JNK modulators
PCT/EP2000/013006 WO2001047920A1 (en) 1999-12-24 2000-12-20 Benzazole derivatives and their use as jnk modulators

Publications (1)

Publication Number Publication Date
HK1055730A1 true HK1055730A1 (en) 2004-01-21

Family

ID=8243214

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03107978A HK1055730A1 (en) 1999-12-24 2003-11-05 Benzazole derivatives and their use as jnk modulators

Country Status (33)

Country Link
US (2) US7259162B2 (et)
EP (2) EP1110957A1 (et)
JP (1) JP4782344B2 (et)
KR (2) KR100736012B1 (et)
CN (1) CN1252067C (et)
AR (1) AR029215A1 (et)
AT (1) ATE254123T1 (et)
AU (1) AU780241B2 (et)
BG (1) BG65986B1 (et)
BR (1) BR0016911A (et)
CA (1) CA2394809C (et)
CZ (1) CZ300984B6 (et)
DE (1) DE60006580T2 (et)
DK (1) DK1240164T3 (et)
EA (1) EA007152B1 (et)
EE (1) EE05456B1 (et)
ES (1) ES2206351T3 (et)
HK (1) HK1055730A1 (et)
HR (1) HRP20020496B1 (et)
HU (1) HU229625B1 (et)
IL (2) IL150346A0 (et)
MX (1) MXPA02006242A (et)
NO (1) NO323146B1 (et)
NZ (1) NZ519423A (et)
PL (1) PL356634A1 (et)
PT (1) PT1240164E (et)
RS (1) RS51008B (et)
SI (1) SI1240164T1 (et)
SK (1) SK287546B6 (et)
TR (2) TR200201509T2 (et)
UA (1) UA73151C2 (et)
WO (1) WO2001047920A1 (et)
ZA (1) ZA200204427B (et)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1300116C (zh) 2001-04-16 2007-02-14 卫材株式会社 1h－吲唑化合物
EP1409483B1 (en) 2001-07-23 2008-12-31 Laboratoires Serono SA Arylsulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors
AU2002352227B2 (en) * 2001-12-07 2007-11-01 Merck Serono Sa Benzazole derivatives for the treatment of scleroderma
DE60318567T2 (de) * 2002-04-25 2009-02-19 Laboratoires Serono S.A., Coinsins Piperazinbenzothiazole als wirkstoffe in der behandlung von ischämien und krankheiten des zns-systems
US7429609B2 (en) 2002-05-31 2008-09-30 Eisai R & D Management Co., Ltd. Pyrazole compound and medicinal composition containing the same
EP1527070B1 (en) 2002-06-14 2013-01-09 Merck Serono SA Azole methylidene cyanide derivatives and their use as protein kinase modulators
AU2003286573B2 (en) 2002-10-23 2009-09-10 Idaho Technology, Inc. Amplicon melting analysis with saturation dyes
CA2524161C (en) 2003-05-08 2013-01-15 Applied Research Systems Ars Holding N.V. Pyridinyl acetonitriles
JP2007505085A (ja) * 2003-09-12 2007-03-08 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ ベンゾイミダゾールアセトニトリル
CA2534319A1 (en) * 2003-09-12 2005-03-24 Applied Research Systems Ars Holding N.V. Benzoxazole acetonitriles
AU2004271740B2 (en) * 2003-09-12 2010-10-28 Merck Serono Sa Benzothiazole derivatives for the treatment of diabetes
CA2561907A1 (en) * 2004-04-08 2005-10-20 Applied Research Systems Ars Holding N.V. Composition comprising a jnk inhibitor and cyclosporin
US9657347B2 (en) 2004-04-20 2017-05-23 University of Utah Research Foundation and BioFire Defense, LLC Nucleic acid melting analysis with saturation dyes
US7387887B2 (en) * 2004-04-20 2008-06-17 University Of Utah Research Foundation Nucleic acid melting analysis with saturation dyes
US7803824B2 (en) 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US20060094753A1 (en) 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
EP1812072B1 (en) * 2004-11-17 2008-10-22 Ares Trading S.A. Benzothiazole formulations and use thereof
US7838522B2 (en) 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
CN101124213B (zh) 2004-12-21 2012-02-01 默克雪兰诺有限公司 磺酰氨基环状衍生物及其应用
KR20070105326A (ko) 2005-01-31 2007-10-30 라보라뚜와르 세로노 에스. 에이. Ｎ-하이드록시아미드 유도체 및 그것의 용도
US20060223807A1 (en) 2005-03-29 2006-10-05 University Of Massachusetts Medical School, A Massachusetts Corporation Therapeutic methods for type I diabetes
KR20080044836A (ko) * 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
BRPI0613042A2 (pt) * 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
AU2006286489B2 (en) 2005-09-01 2012-08-09 Ares Trading S.A. Treatment of optic neuritis
CA2633980A1 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Improved composition for collecting and preserving placental stem cells and methods of using the composition
EP2026802A2 (en) * 2006-06-02 2009-02-25 Laboratoires Serono SA Jnk inhibitors for treatment of skin diseases
US20090194268A1 (en) * 2006-08-28 2009-08-06 Dantherm Air Handling A/S Method for manufacturing a heat exchanger
WO2008100497A1 (en) 2007-02-12 2008-08-21 Anthrogenesis Corporation Hepatocytes and chondrocytes from adherent placental stem cells; and cd34+, cd45- placental stem cell-enriched cell populations
EP2331534A4 (en) * 2008-08-12 2013-01-16 Sirtris Pharmaceuticals Inc BENZOXAZOLES, BENZTHIAZOLES AND RELATED ANALOGUES AS MODULATORS OF SIRTUINE
RU2011113230A (ru) * 2008-09-29 2012-11-10 Телик, Инк. (Us) 2-[1h-бензимидазол-2-(3н)-илиден]-2-(пиримидин-2ил)ацетамиды и 2-[бензотиазол-2-(3н)-илиден]-2-(пиримидин-2-ил)ацетамиды в качестве ингибиторов киназ
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
CN102199147A (zh) * 2011-03-19 2011-09-28 陕西合成药业有限公司 用于治疗的硝基咪唑衍生物
ES2707579T3 (es) 2011-06-01 2019-04-04 Celularity Inc Tratamiento del dolor usando citoblastos placentarios
CN104903331A (zh) * 2013-01-24 2015-09-09 山东亨利医药科技有限责任公司 Jnk抑制剂
AU2014368925A1 (en) * 2013-12-20 2016-07-21 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of MEK type I and ERK inhibitors
KR101520378B1 (ko) * 2014-10-02 2015-05-26 (주)에프테크 습식 가스 스크러버의 배기유도장치
BR112017007178A2 (pt) * 2014-10-08 2017-12-19 Ass Francaise Contre Les Myopathies compostos de aminopiridina úteis como inibidores de prenilação de proteína

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2918369A (en) * 1956-06-15 1959-12-22 Gen Aniline & Film Corp Non-ionic benzimidazole cyanine dyes containing in alpha-position a cyano group on the methenyl chain
GB864131A (en) * 1957-07-17 1961-03-29 Ciba Ltd Benzimidazolyl-acetic acid derivatives
DE1963542A1 (de) 1969-12-18 1971-06-24 Siemens Ag Koppelfeldanordnung fuer Fernmelde-,insbesondere Fernsprechanlagen
JPS51123223A (en) * 1975-04-21 1976-10-27 Fuji Photo Film Co Ltd Process for producing condensation products
CH593954A5 (et) 1975-07-21 1977-12-30 Ciba Geigy Ag
EP0364765A3 (de) * 1988-10-08 1991-07-17 Bayer Ag Substituierte 1,3,5-Triazintrione, Verfahren zu ihrer Herstellung und ihre Verwendung gegen parasitäre Protozoen
US4933341A (en) * 1988-10-08 1990-06-12 Bayer Aktiengesellschaft Substituted 1,3,5-triazinetriones, for use against parasitic protozoa
US5523312A (en) * 1994-09-27 1996-06-04 Sterling Winthrop Inc. Antipicornaviral agents
US6043083A (en) 1997-04-28 2000-03-28 Davis; Roger J. Inhibitors of the JNK signal transduction pathway and methods of use
JP4153574B2 (ja) * 1997-09-10 2008-09-24 トーアエイヨー株式会社 新規なピペリジン誘導体、その製造法およびそれを含有する循環器官用剤
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine

Also Published As

Publication number Publication date
AU780241B2 (en) 2005-03-10
EP1110957A1 (en) 2001-06-27
NO20022997L (no) 2002-06-21
DE60006580D1 (de) 2003-12-18
EE200200318A (et) 2003-10-15
US20070259892A1 (en) 2007-11-08
CZ300984B6 (cs) 2009-09-30
HU229625B1 (hu) 2014-03-28
EE05456B1 (et) 2011-08-15
US7470686B2 (en) 2008-12-30
HRP20020496A2 (en) 2006-03-31
KR20070047853A (ko) 2007-05-07
JP4782344B2 (ja) 2011-09-28
EA200200708A1 (ru) 2003-02-27
AR029215A1 (es) 2003-06-18
CN1433414A (zh) 2003-07-30
UA73151C2 (en) 2005-06-15
US20030162794A1 (en) 2003-08-28
IL150346A (en) 2010-12-30
SK8982002A3 (en) 2002-10-08
PL356634A1 (en) 2004-06-28
RS51008B (sr) 2010-10-31
EP1240164B1 (en) 2003-11-12
SI1240164T1 (en) 2004-04-30
ATE254123T1 (de) 2003-11-15
AU3161601A (en) 2001-07-09
ZA200204427B (en) 2004-02-03
BR0016911A (pt) 2002-10-22
CA2394809A1 (en) 2001-07-05
CA2394809C (en) 2011-03-15
TR200302320T4 (tr) 2004-01-21
KR100736012B1 (ko) 2007-07-06
BG106830A (bg) 2003-02-28
HUP0204557A3 (en) 2009-03-30
WO2001047920A1 (en) 2001-07-05
PT1240164E (pt) 2004-02-27
JP2003519142A (ja) 2003-06-17
NO20022997D0 (no) 2002-06-21
BG65986B1 (bg) 2010-08-31
HRP20020496B1 (en) 2009-03-31
KR20020072282A (ko) 2002-09-14
MXPA02006242A (es) 2003-01-28
HUP0204557A2 (en) 2003-05-28
NZ519423A (en) 2004-04-30
ES2206351T3 (es) 2004-05-16
TR200201509T2 (tr) 2002-09-23
CZ20022169A3 (cs) 2002-09-11
NO323146B1 (no) 2007-01-08
CN1252067C (zh) 2006-04-19
DK1240164T3 (da) 2004-03-01
IL150346A0 (en) 2002-12-01
EP1240164A1 (en) 2002-09-18
SK287546B6 (sk) 2011-01-04
US7259162B2 (en) 2007-08-21
YU49202A (sh) 2006-01-16
EA007152B1 (ru) 2006-08-25
DE60006580T2 (de) 2004-09-16

Similar Documents

Publication Publication Date Title
HK1055730A1 (en) Benzazole derivatives and their use as jnk modulators
IL149374A0 (en) New use and novel n-azabicyclo-amide derivatives
HRP20060251B1 (hr) Supstituirani oksazolidinoni i njihova uporaba
IL147924A0 (en) Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents
GB0004167D0 (en) 1-piperidinyl-propan-2-ol derivatives and their use as therapeutic agents
PL349355A1 (en) Diaryl derivatives and their application as therapeutic agents
AU4923200A (en) Isothiazolecarboxamides and their use as microbicides
HUP0203896A3 (en) Substituted 8-arylquinoline phosphodiesterase-4-inhibitors and use thereof
HU0001396D0 (en) 3-amino-3-arylpropan-1-al derivatives and their use
AU1164601A (en) Therapeutic use and formulation
AU8975801A (en) Novel indole derivatives and their use as medicaments
GB0023323D0 (en) Arylhydantoin derivatives and uses thereof
PL367676A1 (en) Novel heterocyclic derivatives and medicinal use thereof
EP1194147A4 (en) DERIVATIVES OF ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE
IL147645A0 (en) Rest-breaking composition and use thereof
AU4129800A (en) Bis-benzazoles and their use as antineoplastic agents
GB9824160D0 (en) Heterocyclic compounds and their therapeutic use
AU2669201A (en) Taccalonolides and their use
AU5974100A (en) 6-carboxyphenyldihydropyridazinone derivatives and use thereof
GB9919971D0 (en) Use
AU6150400A (en) Tetrahydroquinolinyl-6-methyldihydrothiadiazinone derivatives and use thereof
GB9911606D0 (en) Composition and use
GB9929581D0 (en) Comjpositions and their use
GB9911238D0 (en) Therapeutic use
GB9903919D0 (en) Aminophenols and their therapeutic use

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE NAME OF INVENTOR FROM MONTSERRAT CAMPAS TO MONTSERRAT CAMPS

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20151220